Home / Clinical Decision Support & Reference / BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

by BIO-RAD LABORATORIES · Based in United States → — Advanced Multiplex Immunoassay System with AI-Powered Medical Decision Support for Autoimmune and Infectious Disease Diagnostics

Infectious Disease Laboratory Medicine Rheumatology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Contact for pricing

Regulatory Status Disclosed

Overview

The BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM is a fully automated, random access multiplex immunoassay system designed for clinical laboratories. It is not an AI tool for a physician directory, but rather a sophisticated in vitro diagnostic (IVD) system with integrated software to aid in the diagnosis of systemic autoimmune diseases and other conditions.

The system utilizes multiplex bead technology to simultaneously detect and differentiate multiple autoantibodies and other analytes from a single patient sample, improving workflow efficiency and turnaround time compared to traditional single-analyte methods. The Medical Decision Support Software (MDSS) is an optional feature that employs an interpretive software algorithm, specifically a k-Nearest Neighbor (kNN) algorithm, to associate patient antibody results with predefined profiles correlated with specific connective tissue diseases such as Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sjögren’s Syndrome (SS), Scleroderma (Systemic Sclerosis), and Polymyositis. This provides clinicians with valuable, actionable information to support faster diagnoses and improved patient outcomes.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

Fully automated random access system
Multiplex immunoassay technology (up to 25 analytes per tube)
Medical Decision Support Software (MDSS) with interpretive algorithm (kNN)
High throughput (up to 1200-1400 patient results per hour)
Simultaneous detection of multiple autoantibodies and analytes
Reduced hands-on time and labor costs
Internal quality control beads for reliable results
Consolidation of autoimmune, infectious disease, and vitamin D testing
Interfaces with Laboratory Information Systems (LIS)
Aids in diagnosis of systemic autoimmune diseases

Use Cases

Screening and diagnosis of systemic lupus erythematosus (SLE)
Diagnosis of mixed connective tissue disease (MCTD)
Diagnosis of Sju00f6gren's syndrome (SS) and scleroderma
Detection of autoantibodies for vasculitis, rheumatoid arthritis, and celiac disease
Testing for infectious diseases (e.g., HIV, Syphilis, EBV, ToRC)
Vitamin D testing

What Physicians Need to Know

Evidence Base

The Medical Decision Support Software (MDSS) utilizes an interpretive software algorithm developed from over 15,000 test results across more than 1,400 clinically characterized patients. It associates patient autoantibody profiles with specific connective tissue diseases (CTDs). The system detects clinically significant autoantibodies to aid in the diagnosis of systemic autoimmune diseases, including Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sju00f6gren's Syndrome (SS), Scleroderma (Systemic Sclerosis), and Polymyositis. The BioPlex 2200 ANA Screen has been compared to traditional methods like HEp-2 IFA and ELISA.

Clinical Validation Studies

The MDSS algorithm was developed and validated using a diverse cohort of over 1,400 characterized samples, yielding more than 15,000 results. Comparative studies have shown that the BioPlex 2200 ANA Screen offers similar or superior clinical performance compared to traditional HEp-2 IFA and ELISA methods for initial ANA testing. A study involving 510 healthy subjects assessed the specificity of the BioPlex 2200 ANA Screen. Another study compared its performance with a conventional chemiluminescence enzyme immunoassay (CLEIA) using 106 patient samples with connective tissue diseases. Precision studies, conducted according to CLSI EP5-A guidelines, demonstrated excellent intra-assay (2.5u20134.7% CV) and inter-assay (6.8u20138.6% CV) reproducibility.

Differential Diagnosis Support

The MDSS provides direct support for differential diagnosis by associating positive ANA result profiles with specific systemic autoimmune diseases. It can suggest possible disease associations, including Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Sju00f6gren's Syndrome (SS), Scleroderma (Systemic Sclerosis), and Polymyositis. The software may propose up to two disease classifications based on the individual autoantibody results from the ANA Screen panel.

Clinical Workflow Integration

The BioPlex 2200 System, with its MDSS, is a fully automated, random-access multiplex system designed to streamline ANA testing workflows. It enables simultaneous detection of multiple autoantibodies in a single reaction tube, which helps eliminate the need for separate follow-up testing. This multiplex technology aims to accelerate result turnaround time, boost throughput (up to 1,400 results per hour outside the U.S., 1,200 in the U.S.), and reduce operational costs by consolidating testing. Integrated quality control beads are processed with every sample to ensure system and result reliability.

Physician Tip

The BioPlex 2200 ANA Screen with MDSS serves as a valuable aid in the diagnosis of systemic autoimmune diseases. Physicians should interpret MDSS associations in conjunction with clinical findings and other laboratory tests, as the software provides potential disease classifications based on autoantibody profiles. The ability to detect multiple clinically relevant autoantibodies simultaneously and receive interpretive guidance can help streamline the diagnostic process for conditions like SLE, MCTD, Sju00f6gren's Syndrome, Scleroderma, and Polymyositis, potentially leading to faster diagnoses and improved patient outcomes.

The BioPlex 2200 System is a fully automated, multiplex platform that integrates ANA screening and follow-up testing into a single step. This integration significantly enhances laboratory efficiency by reducing hands-on time, improving throughput, and optimizing the management of ANA workloads. Its design allows for seamless incorporation into existing laboratory workflows, minimizing the need for multiple test methods and manual processes, thereby reducing operational costs and improving overall turnaround time for results.

At a glance

Pricing Contact for pricing

Deployment On Premise (clinical Laboratories, Hospitals, National Reference Laboratories, Public Health Laboratories)

Visit site

Details

Category	Clinical Decision Support & Reference, Lab & Diagnostics
Pricing	Contact for pricing
Deployment	On-premise (clinical laboratories, hospitals, national reference laboratories, public health laboratories)
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated The device, including the Medical Decision Support Software (MDSS), received FDA marketing clearance (K043341) on October 27, 2005. It is cleared for correlating patient antibody results with specific autoimmune diseases, making it the first product of its kind to be FDA-cleared for this purpose.
Integrations
EHR	Not specified
Specialties	Infectious Disease, Laboratory Medicine, Rheumatology

What the Web Says

The BioPlex 2200 ANA Screen with Medical Decision Support Software (MDSS) is a fully automated, multiplexed system designed to detect and differentiate clinically relevant antinuclear antibodies (ANA) to aid in the diagnosis of systemic autoimmune diseases. It offers faster turnaround times and can provide up to 14 individual results per test, including a composite ANA screen and up to 13 specific ANA analytes. The MDSS is an optional feature that uses an interpretive algorithm to associate patient antibody results with specific autoimmune diseases, providing valuable diagnostic information to physicians.

Overall: Positive

Strengths

Faster result turnaround time due to multiplex technology, potentially leading to quicker diagnoses and improved patient outcomes.
Provides multiple results per test (up to 14 individual results), streamlining ANA screening and follow-up testing in one step.
Medical Decision Support Software (MDSS) offers interpretive algorithms to associate antibody profiles with specific autoimmune diseases, a feature not previously available in clinical diagnostic systems.
High throughput capability, processing up to 1200-1400 results per hour, which can reduce hands-on time and labor costs.
Improved sensitivity compared to traditional IIF on HEp-2 cells for detecting clinically relevant autoantibodies.
Reduces operational costs by minimizing the need for separate follow-up tests and expanding in-house testing menus.

Limitations

Some studies show discrepancies between BioPlex 2200 ANA screening and IIF ANA screening results, although concordance is good for specific anti-dsDNA and anti-ENA antibodies.
A particular concern for some users was that the system does not provide an IIF pattern and titer, which is a traditional method for ANA detection.
The BioPlex 2200 has a lower positive rate than IIF for autoantibody screening in healthy subjects.

Based on reviews from: Bio-Rad, PubMed, ResearchGate, BioSpace, myadlm.org, accessdata.fda.gov, Clinical Pathology Laboratories

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

BioSpace

Bio-Rad Laboratories, Inc. Receives FDA Clearance For Novel Interpretive Software Used For Autoimmune Testing

Bio-Rad Laboratories received FDA marketing clearance for its Medical Decision Support Software (MDSS) for use with the BioPlex 2200 ANA Screen and BioPlex 2200 System. This software is the first FDA-cleared product of its kind to correlate patient antibody results with specific autoimmune diseases.

2005-11

Clinical Pathology Laboratories

ANA Screen with Interpretation by MDSS - Clinical Pathology Laboratories

Clinical Pathology Laboratories (CPL) will introduce antinuclear antibodies (ANA) screening with interpretation by medical decision support software (MDSS) on Bio-Rad Bioplex 2200, effective September 22, 2025. This system uses multiplex flow immunoassay to detect 11 autoantibodies and aid in diagnosing systemic autoimmune diseases.

2025-09

accessdata.fda.gov

BioPlexu00ae 2200 ANA Screen with MDSS 510(k) Summary - accessdata.fda.gov

This FDA 510(k) summary details the BioPlex 2200 ANA Screen with Medical Decision Support Software (MDSS) as an aid in diagnosing systemic autoimmune diseases. The MDSS correlates patient antibody results with predefined profiles for conditions like Systemic Lupus Erythematosus (SLE) and Sju00f6gren's Syndrome.

2012-06

Bio-Rad

BioPlex 2200 ANA Screen - Bio-Rad

The BioPlex 2200 ANA Screen, with optional Medical Decision Support Software (MDSS), simplifies the interpretation of ANA assay results by associating antibody profiles with connective tissue diseases. It uses multiplex technology for faster turnaround times and provides up to 13 individual, clinically relevant results.

unknown

accessdata.fda.gov

BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION ...

This document is a regulatory filing concerning the BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM.

2005-10

Bio-Rad

BioPlexu00ae 2200 ANA Screen with MDSS - Bio-Rad

The BioPlexu00ae 2200 ANA Screen with Medical Decision Support Software (MDSS) enhances the diagnosis of systemic autoimmune diseases by detecting clinically significant autoantibodies. The fully-automated system minimizes human error and improves clinical specificity, reducing false positives.

unknown

Videos

Product demos, reviews, and walkthroughs for BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

How does the BIOPLEX 2200's medical decision support software integrate into my current diagnostic workflow for ANA screening, and what is the expected learning curve?

The BioPlex 2200 ANA Screen with Medical Decision Support Software (MDSS) is designed to streamline ANA testing by providing a fully automated multiplex immunoassay that detects multiple autoantibodies simultaneously. It aims to reduce hands-on time and accelerate turnaround time compared to traditional methods like IFA or individual EIA tests. The MDSS offers interpretive software that associates patient antibody results with predefined profiles correlated to specific systemic autoimmune diseases, potentially simplifying result interpretation.

What regulatory clearances (e.g., FDA) does the AI decision support software hold, and how does it ensure patient data privacy and security in line with regulations like HIPAA?

The BioPlex 2200 ANA Screen with MDSS is FDA cleared, and it is noted as the first and only FDA cleared autoimmune product with an interpretive software algorithm. While specific details on data privacy within the product are not extensively detailed in public summaries, AI-based medical devices in healthcare are subject to stringent regulations like HIPAA to ensure patient confidentiality and data security. Healthcare organizations adopting such AI tools are responsible for conducting security risk assessments and ensuring compliance with data handling practices.

How does the diagnostic performance and efficiency of this AI-enhanced system compare to traditional ANA screening methods or other commercially available automated platforms?

The BioPlex 2200 ANA Screen utilizes multiplex technology to provide up to 14 individual results per test, offering higher throughput and potentially faster diagnoses than traditional single-analyte methods. Studies suggest that it can offer similar or superior clinical performance compared to traditional HEp-2 IFA, and its results may be more predictive of future connective tissue disease diagnoses. However, some studies have noted discrepancies between BioPlex and IFA results, highlighting the importance of considering clinical history alongside test findings.

What is the overall cost structure for the BIOPLEX 2200 system, including the medical decision support software, and what are the implications for reimbursement and practice economics?

Specific pricing for the BioPlex 2200 system and its MDSS is typically obtained through direct inquiry with Bio-Rad. However, multiplexing technology generally aims to reduce operational costs by consolidating multiple tests into a single assay, potentially lowering the cost per patient result and reducing the need for separate follow-up testing. Reimbursement for ANA and ENA tests performed on the BioPlex 2200 would typically follow established CPT codes, with individual analytes often billed separately.

What are the specific limitations or potential biases of the AI decision support software in interpreting complex or borderline ANA results, and how should these be clinically managed?

The MDSS results should always be considered in conjunction with the patient's clinical presentation and other laboratory findings, as it does not rule out autoimmune disease if interpreted as 'Negative' or 'No Association'. Limitations include potential false-negative results in SLE patients on steroid or immunosuppressant therapy, and caution is advised when interpreting results for patients with Rheumatoid Arthritis due to possible SLE associations. AI models in healthcare can carry risks of bias if trained on incomplete or unrepresentative data, underscoring the need for human oversight and clinical judgment.

To what extent can I understand the AI's reasoning behind its diagnostic suggestions, and what mechanisms are in place for me to exercise clinical override?

The BioPlex 2200 MDSS uses an interpretive algorithm based on the k-nearest neighbor statistical technique, trained with over 15,000 test results from characterized samples to suggest disease associations. While the software provides suggested disease associations, the principle of 'Interpretable AI' emphasizes that clinicians should understand and scrutinize AI predictions, maintaining the ability to exercise clinical override based on their comprehensive judgment. This human-centered approach ensures that AI complements, rather than replaces, professional expertise.

What data sets and methodologies were used to validate the AI model's performance, and how does it account for variability across different patient demographics and disease presentations?

The MDSS algorithm was developed using over 1400 characterized samples with over 15,000 results, and its performance has been validated through studies comparing it to conventional methods. The system detects 11 clinically relevant autoantibodies to aid in diagnosing systemic autoimmune diseases. While the MDSS aims to identify diagnostic patterns, the broader challenge for AI in healthcare involves ensuring model generalizability and addressing variability across diverse patient populations, which requires ongoing validation and consideration of diverse clinical data.

Compare BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM

BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM vs Regard

Clinical Decision Support & Reference Adjacent · 60/100

While both tools offer AI-powered clinical decision support, they target different stages of the diagnostic workflow. BioPlex 2200 focuses on automated multiplex immunoassay testing and interpretation for specific…

BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM vs University of Birmingham

Clinical Decision Support & Reference Adjacent · 60/100

Tool A is a specialized, FDA-cleared diagnostic system for autoimmune and infectious diseases, providing automated multiplex immunoassay testing with interpretive software. Tool B, developed by the University of…

BIOPLEX 2200 ANA SCREEN WITH MEDICAL DECISION SUPPORT SOFTWARE FOR USE WITH BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM vs Kahun

Clinical Decision Support & Reference Adjacent · 65/100

Tool A is a specialized laboratory system for automated immunoassay testing and interpretation of autoimmune and infectious diseases. Tool B is a broader AI-powered clinical reasoning platform that…